Zehra Parlak
CEO
QATCH Technologies
The startup has developed a pre-screening tool that integrates microfluidic and acoustic technologies to process nanoliter volumes for viscosity measurement. This enables biopharma researchers to efficiently identify optimal injectable molecules while minimizing liquid volume requirements.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$250KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
During biopharmaceutical drug development, traditional methods for assessing viscosity and injectability require large sample volumes, which can be a limiting factor, especially in early stages when material is scarce. These methods may also be time-consuming and lack the throughput needed for efficient formulation screening.
Solution
QATCH Technologies offers a microfluidic viscometer that enables biopharmaceutical researchers to efficiently prescreen drug formulations for injectability and manufacturability using nanoliter sample volumes. The technology utilizes acoustic measurements to determine viscosity across a wide range of shear rates, providing data-rich insights with minimal material consumption. This allows for early identification of optimal injectable molecules and de-risks the preclinical phase of drug development by predicting potential viscosity-related manufacturing problems. The system requires no cleaning or priming, and provides results in approximately five minutes.
Target Audience
The primary target audience includes biopharmaceutical drug discovery teams and formulation scientists involved in early-stage drug development and formulation screening.
Features
- Microfluidic technology for viscosity measurement using only 5 microliters of sample
- Acoustic sensor technology to measure viscosity across five decades of shear rates
- Rapid measurement time of approximately 5 minutes
- No cleaning or priming required between measurements
- Proprietary technology to de-risk preclinical phase for biopharmaceutical drug development
- Enables early identification of optimal injectable molecules
- Predicts potential viscosity-related manufacturing problems